Wedbush Reduces Earnings Estimates for Vigil Neuroscience

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Research analysts at Wedbush dropped their FY2027 earnings per share estimates for Vigil Neuroscience in a report issued on Thursday, May 22nd. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($2.13) for the year, down from their prior estimate of ($1.53). Wedbush has a "Hold" rating and a $8.00 price target on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share. Wedbush also issued estimates for Vigil Neuroscience's FY2028 earnings at ($2.39) EPS and FY2029 earnings at ($1.18) EPS.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04.

Other equities analysts have also recently issued research reports about the company. Citizens Jmp cut Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. JMP Securities restated a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Jefferies Financial Group cut Vigil Neuroscience to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright cut Vigil Neuroscience from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $14.00 to $8.00 in a report on Tuesday. Finally, William Blair cut Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. Ten analysts have rated the stock with a hold rating, According to MarketBeat, Vigil Neuroscience has an average rating of "Hold" and a consensus target price of $10.80.

Vigil Neuroscience Stock Performance

Vigil Neuroscience stock traded down $0.01 during midday trading on Monday, reaching $7.89. 597,141 shares of the company's stock were exchanged, compared to its average volume of 649,529. Vigil Neuroscience has a 52 week low of $1.31 and a 52 week high of $7.95. The firm has a market cap of $368.01 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. The stock's 50-day simple moving average is $2.55 and its 200 day simple moving average is $2.39.

Institutional Investors Weigh In On Vigil Neuroscience

A number of hedge funds and other institutional investors have recently made changes to their positions in VIGL. Cubist Systematic Strategies LLC raised its position in shares of Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after buying an additional 8,358 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Vigil Neuroscience in the fourth quarter valued at approximately $83,000. Barclays PLC raised its position in shares of Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after buying an additional 19,436 shares in the last quarter. Northern Trust Corp raised its position in shares of Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after buying an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP raised its position in shares of Vigil Neuroscience by 243.8% in the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock valued at $117,000 after buying an additional 49,000 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.